Generally, when planning, project teams have a broad picture of the goal or process in aim but typically forget the sudden risks found during the development. The planning process should be narrowed down into more specific details about each step of the plan, and as it goes, risk management assessment is applied. This approach leads to risk analysis and a risk management questionnaire to evaluate risks, decide on controls, record findings, and access a prompt response. Nevertheless, risks will still be onboard but manageable to the industry rather than affecting patient care. According to ISO 14971, the risk is a combination of the probability of occurrence of harm and the severity of that harm.   
Indeed, continuous risk assessment management covers all life cycles of the medical device; it needs to be run along with design controls to ensure the benefits and rewards are slowly compounding for project success. After all, risk management of medical devices is intended to assist manufacturers in identifying potential risks, controlling risks, and monitoring the effectiveness of controls.

A structured, continuous approach to risk assessment, as outlined in ISO 14971, is key to preventing overlooked hazards. Narrowing the planning process into specific steps allows teams to focus on each task and identify potential pitfalls early, rather than waiting for surprises. This detailed perspective aids in gathering the right data, deciding on proper controls, and preparing contingency responses—ultimately reducing both the likelihood and severity of harm to patients.

By integrating risk assessment with design controls from the outset, manufacturers can manage and refine their strategies at every stage of the medical device’s life cycle. While it’s inevitable that some risks remain, a well-implemented risk management system helps ensure that these risks are kept within acceptable limits. Continuous monitoring and evaluation mean issues can be identified quickly, corrective actions taken, and benefits gradually realized over time. In this way, risk management not only protects patients but also supports the overall success and sustainability of the project.

One thing to consider with medical devices is that they don't all carry the same level of risks, hence the classification. Implementing different risk-adaptive techniques for different classifications can speed up the process for Class I medical devices, as they pose less risk compared to Class II or Class III devices. Another thing that can help speed up the process is determining which risks must be addressed before the late stages, and which risks can be easily addressed during the late stages of the project lifespan. This allows flexibility for low risks if they appear during the project lifespan as circumstances may change by then. This allows for a more hybrid approach and requires less slow-down on the project progress. 

We can determine the risks which are worth taking by evaluating the residual risk evaluation. Ask yourself on a high level whether the product’s overall residual risk should be considered acceptable. This is really a question of whether your product is better or worse or on par with every other product in the field.

1. Ensure that you compile and communicate the residual risks of your medical device. 
2. One way to understand overall residual risk acceptability is to compare two products 
3. You could compare the risks associated with your product with competitors, have application specialists or experts review your product, or use expert judgment

We should prioritize risk management in balance with speed of development. The product should not have ample risk with it that it harms humans, and also not delayed consuming resources and manpower.

Companies with robust risk management processes know how to stop, pivot and quickly change direction without losing focus of their strategic initiatives.

The risk management process should cover the whole life cycle of the device, from initial conception to decommissioning. This means that you should include risks arising from things such as: 

• poor design, 
• failure in production processes, 
• rough handling during shipping, 
• software bugs, 
• misuse by a user, 
• side effects from using the medical device, 
• component failures, and 
• risks arising during scrapping.  
  

The risk management process must not only be documented, but management should ensure it is effective. Therefore, it is the management’s responsibility to review the suitability of the risk management process at planned intervals to guarantee the effectiveness of it. This requirement should not be confused with risk management review, which is a different activity.  There are also other risk management tools, Fault Tree Analysis (FTA), Risk Matrix and Risk Priority Number.

We should prioritize early stage risk assessment. A risk management file needs to be created and maintained. Important parts of the risk management file are the risk management plan and the risk management report, which is created after the review of the execution of the plan.

Effective risk management in medical device development requires balancing safety, efficiency, and cost. While minimizing risk is essential (especially under ISO 14971 guidelines), overly cautious approaches can delay innovation and inflate costs. It is important to prioritize early-stage risk assessments to help identify and mitigate major hazards upfront, reducing the likelihood of costly redesigns later. However, not all risks warrant immediate action; some can be monitored and addressed as development progresses. The key is to evaluate risks based on severity, probability, and detectability, ensuring that critical failures are prevented while allowing manageable risks to support timely product development.

In my opinion, another key question to ask at the start of the risk assessment process is:

"What level of risk is acceptable, and how do we define an acceptable risk?"

This forces teams to establish clear risk thresholds based on patient safety, regulatory requirements, and business priorities. Some risks might be tolerable if they don’t compromise safety or compliance, while others must be mitigated no matter the cost.

?

Enhancing our approach with quantitative risk analysis and metrics is essential. Incorporating numerical methods—such as risk scoring, probability assessments, and simulation tools like Monte Carlo analyses—can transform qualitative insights into measurable data. This approach enables more objective tracking of risk mitigation efforts, better trend identification, and more informed prioritization of risks based on their potential impact.

Another crucial aspect is addressing cybersecurity and ensuring data integrity. With the increasing integration of software and connectivity in medical devices, robust cybersecurity measures are necessary to safeguard patient information and maintain device functionality. Implementing secure data protocols and adhering to cybersecurity standards not only protects against external threats but also reinforces overall trust in the product’s safety and reliability.

Lastly, establishing a strong post-market surveillance system and creating effective feedback loops are critical. Continuous monitoring after product launch provides valuable real-world data, allowing for the timely detection of emerging risks. This information should feed back into the risk management process, ensuring that mitigation strategies are updated and refined over the entire lifecycle of the device. Such an integrated, data-driven approach will help maintain high safety standards while supporting innovation and efficiency in development. 

Risk management is particularly important for medical devices since regulatory, technical, and market risks can jeopardize timelines or even result in complete failure. If a team doesn't assess risk early on, they might be compelled to undergo additional testing, experience problems with the supply chain, and face penalties for noncompliance, all of which can result in cost escalations and deadlines being missed.

Miscalculating compliance risks such as not factoring in increased biocompatibility or extra clinical testing is a classic example of this oversight. Another is assuming that supply chain constraints, particularly regarding a lack of materials, will not impact production if there are no backup plans.

To avoid problems, it is suggested that risks should be analyzed and evaluated to develop appropriate strategies to mitigate the risks observed and constantly re-visit new risks over the course of the project. This allows the team to ensure that they are constantly ahead of any issues, instead of playing damage control after the fact.

What do you think is the area most overlooked in medical device projects—technical feasibility, regulatory requirements, or market adoption? Do you feel there are better steps to ensure preparedness against these uncertainties?

@sarahqudah1 I believe that with medical device projects, market adoption is one of the more overlooked issues. Cost and accessibility of the product are important to consider in the creation of it. High development costs create high costs of product, with materials typically being specialized for medical application, expertise needed in creation and management of quality of products, and creating awareness of the product. It is also important to know who stakeholders and customers are with medical device projects. While patients are using products, doctors will likely be implementing them. On another level, while doctors implement products, hospitals are businesses who seek profit from use of said product and distribute it to physicians. It is important to get feedback from all parties involved, a facet overlooked with a hyper-focus on the perspective of patients or physicians.

Early-stage risk assessments are less expensive than addressing the risks as they arise. Taking risks should not come at the expense of safety, and their significance depends on their severity and probability. Realistically, certain risks may be accepted, but the decision-making should not be done hastily or at the last minute. Risk responses should be practical for the project's success, meaning they are cost-effective and justifiable, which should prevent excessive caution and extreme delays. What can also contribute to excessive caution, or not enough, is an overemphasis on outputs rather than outcomes. For example, a project team goes after the first solution rather than spending the resources needed to identify the alternative that yields better results. That said, addressing risk is one thing, but taking steps to mitigate or resolve it may require stakeholder approval beforehand. It would also be of best interest to have a responsible person tied to the risk so that the response is completed and monitored accordingly. 

I think early stage risk assessments are very important especially in medical device development where safety and regulatory compliance are critical. Tools like FMECA can be helpful because they allow teams to identify high severity or high probability failures early and focus resources on mitigating those risks first which could help prevent costly redesigns later in the development process. Also at the same time, not all risks need to be eliminated if they have low severity or can be controlled through verification testing. In my opinion, the goal is to prioritize the risks that could impact patient safety, regulatory approval or core device functionality while accepting manageable risks that do not significantly affect those areas. Balancing risk this way allows teams to stay compliant with ISO standards while also still maintaining timelines.

Balancing risk and reward in medical device development is less about eliminating all risk and more about managing risk to an acceptable level while still making progress. Standards like International Organization for Standardization’s ISO 14971 describe a structured process where hazards are identified, evaluated, and mitigated throughout the development of the product. This means risk management should start early because initial risk assessments are generally less expensive and easier to address than problems discovered during verification, validation, or clinical testing.

That being said, it is not realistic or efficient to minimize risk at all costs. Some level of risk acceptance is necessary to maintain reasonable timelines and development costs. Companies should install a risk based decision network that prioritizes mitigation for high-severity or high-probability risks, while monitoring lower-risk issues as the project progresses. By utilizing frequent risk reviews with project milestones, teams can move forward efficiently while still ensuring patient safety and regulatory compliance remain the primary focus.

Balancing risk and reward is one of the biggest challenges in risk management. While minimizing risk is necessary, trying to eliminate every possible risk can slow down development and increase costs. It is best practice to focus on reducing risks to an acceptable level rather than trying to completely remove all risks. For example, a company developing a syringe delivery system might identify a minor risk that leakage could occur under extreme temperature conditions during storage. Completely eliminating this risk could require redesigning the syringe with different materials or packaging. This would substantially increase costs and potentially delay launching the product. If testing shows that the probability of leakage occurring is very low and the severity is minimal, it may be better for the company to accept the risk. This decision allows companies to balance cost, project timelines, and safety while remaining compliant with ISO 14971 guidelines.